HomeProtein ExpressionDopamine Receptors

Dopamine Receptors

Dopamine receptors were initially differentiated into two major types based on the ability of dopamine to stimulate (D1) or inhibit (D2) adenylyl cyclase activity and produce the second-messenger molecule cyclic-AMP (cAMP). Extraordinary advances in molecular genetics have greatly facilitated the isolation and characterization of novel dopamine receptors, D3, D4 and D5, with different anatomical localization from traditional D1 or D2 receptors. Based upon their peptide sequences, pharmacological profiles, including their effects on different signal transduction cascades, the five dopamine receptors are currently divided into two families; the D1-like family, which includes D1 and D5 receptors, and the D2-like family, which includes D2, D3 and D4 receptors. The dopamine receptors are coupled to G-proteins and modified by attached carbohydrate, lipid-ester or phosphate groups. They are characterized by having seven hydrophobic transmembrane-spanning regions, as well as a functionally third intracytoplasmic loop that interacts with G-proteins and other effector molecules to mediate the physiological and neurochemical effects of the receptors.

Dopamine D1 and D2 receptors are widely expressed in forebrain regions and occur in tissues at sufficiently high concentrations so that they can be studied in situ. Other receptors (D3, D4 and D5) have more limited distribution and occur at such low concentrations that experimental investigation of the receptors in situ is more difficult. These latter receptors and their proposed effector mechanisms have been studied subsequent to their expression in genetically transfected cell lines, but care must be taken in extrapolating the results obtained with the cloned receptor to the in vivo situation.

Identification of compounds that discriminate between D1-like and D2-like receptors strongly supports division of the dopamine receptors into two families. However, most drugs and candidate ligands bind with high affinity to more than one dopamine receptor subtype to hinder comprehensive pharmacological and neurobiological characterization of each dopamine subtype. No agents have been identified that are selective for D1 versus D5 receptors, for example, and most compounds targeting D2-like receptors have substantial affinity for more than one member of the family.

Mice with targeted gene depletion of specific dopamine receptor subtypes have been developed using recombinant DNA technologies with embryonic stem cells. Such gene "knock-out" mutant mice provide valuable models for studies of physiological and behavioral effects of dopamine receptors. However, such findings should be interpreted carefully since phenotypic variability, genetic background, and complex compensatory developmental adaptations may influence outcomes due to factors other than the absence of specific dopamine receptor genes. Advancing research on dopaminergic systems requires empirical searching for improved, more selective, novel ligands for dopamine receptor subtypes, guided by better understanding of the molecular, cellular, and behavioral physiology and neuropharmacology of this important class of cerebral receptors.

Illnesses for which dopamine receptor agonists or antagonists are clinically useful are common, usually chronic, and their current treatments are imperfectly palliative and limited by adverse-effects. Dopamine D1 and D2 agonists are effective in improving symptoms of Parkinsons disease (PD). Antagonistic activity at D2 receptors remains an essential component in the pharmacological profiles of standard and newer antipsychotic drugs developed for treatment of schizophrenia and other idiopathic psychotic disorders. D3 receptor ligands showed evidence of antagonizing reinforcing behaviors of cocaine and alleviating levodopa-induced dyskinesia in patients with PD. Preclinical studies are encouraging the development of dopamine D4-selective compounds for treatment of attention-deficit hyperactivity disorder and other conditions that commonly involve attentional and cognitive dysfunctions. In addition, these agents are being considered as potential novel treatments for erectile dysfunction. The recent evidence, which indicates that D5 receptors play a pivotal role in blood pressure regulation, suggests that D5-selective compounds, once developed, may prove useful for treatment of hypertension. All these circumstances continue to make dopamine receptors attractive pharmacotherapeutic targets for improved treatment of neuropsychiatric and other disorders.

The Table below contains accepted modulators and additional information. For a list of additional products, see the "Similar Products" section below.


a) Deduced aa composition of putative third cytoplasmic loop differs between short and long isoforms.

b) Deduced aa composition of putative third cytoplasmic loop varies due to the presence of 40 base pair repeats. The number of repeats is sometimes indicated (e.g., D4.2 for two repeats).


A-369508: 2-[4-(2-Cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide
A-381393: 2-[4-(3,4-Dimethylphenlyl)piperazin-1-ylmethyl]-1H-benzoimidazole
A-68930: 1R,3S-1-Aminomethyl-5,6-dihydroxy-3-phenylisochroman hydrochloride
A-77636: (–)-(1R,3S)-3-Adamantyl-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran
A-86929: (–)-trans-9,10-Hydroxy-2-propyl-4,5,5a,6,7,11b-hexahydro-3-thia-5-azacyclopent-1-ena[c]phenanthrene hydrochloride
ABT-724: 2-(4-Pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole
BP 897: N-[4-[4-(2-Methoxyphenyl)-1-piperazinyl]butyl]-2-naphthylcarboxamide
CP-226,269: 5-Fluoro-2-[[4-2(2-pyridinyl)-1-piperazinyl]methyl]-1H-indole
CP-293,019: 7-[(4-Fluorophenoxy)methyl]-2-(5-fluoro-2-pyrimidinyl)octahydro-(7R,9aS)-2H-pyrido[1,2-a]pyrazine
GR 103,691: {4'-Acetyl-N-{4-[(2-methoxy-phenyl)-piperazin-1-yl]-butyl}-biphenyl-4-carboxamide
KCH-1110: 1-(2-Ethoxy-phenyl)-4-[3-(3-thiophen-2-yl-isoxazolin-5-yl)-propyl]-piperazine
L-741,626: (±)-3-[4-(4-Chlorophenyl)-4-hydroxypiperidinyl]-methylindole
L-745,870: 3-([4-(4-Chlorophenyl)piperazin-1-yl]methyl)-1H-pyrrolo(2,3-b)pyridine
L-750,667: (±)-3-[4-Iodophenyl)-1-piperazyl]methylpyrrolo[2,3-b]pyrimidine
7-OH-DPAT: 2-Dipropylamino-7-hydroxy-1,2,3,4-tetrahydronaphthalene
R(+)-7-OH-DPAT: R(+)-2-Dipropylamino-7-hydroxy-1,2,3,4-tetrahydronaphthalene
7-OH-PIPAT: (+)-7-Hydroxy-2-(N-n-propyl-N-3′-iodo-2-propenyl)aminotetralin
PD 128,907: 3,4,4a,10b-Tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol
PD 168,077: N-[[4-(2-Cyanophenyl)-1-piperazinyl]methyl]-3-methyl-benzamide
RBI-257: 1-[4-Iodobenzyl]-4-[[2-[3-isopropoxy]pyridyl]-methylamino]piperidine
SB 277011-A: trans-N-[4-[2-(6-Cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide
SCH-23390: 7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
SCH-39166: (–)-trans-6,7,7a,8,9,13b-Exahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo-[d]-naphto-[2,1b]-azepine hydrochloride
TNPA: R(-)-2,10,11-trihydroxy-N-propyl-noraporphine hydrobromide
R(+)-SKF-38393: 1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol
U-101,387: 4-[4-[2-[(1S)-3,4-Dihydro-1H-2-benzopyran-1-yl]ethyl]-1-piperazinyl]-benzenesulfonamide
U-91,356A: (R)-5,6-Dihydro-5-(propylamino)-4H-imidazo[4,5,1-ij]quinolin-2-(1H)-one monohydrochloride
U99194A: 5,6-Dimethoxy-2-(N-dipropyl)-aminoindan

Similar Products


Ahlgren-Beckendorf JA, Levant B. 2004. Signaling Mechanisms of the D3Dopamine Receptor. Journal of Receptors and Signal Transduction. 24(3):117-130.
Baldessarini RJ, Tarazi FI. 1996. Brain Dopamine Receptors: A Primer on Their Current Status, Basic and Clinical. Harv Rev Psychiatry. 3(6):301-325.
Banerjee A, Prante O. 2012. Subtype-Selective Dopamine Receptor Radioligands for PET Imaging: Current Status and Recent Developments. CMC. 19(23):3957-3966.
Crider A, Scheideler M. 2001. Recent Advances in the Development of Dopamine D3 Receptor Agonists and Antagonists. MRMC. 1(1):89-99.
Exley R, Cragg SJ. Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. 153(S1):S283-S297.
Kabbani N, P. Woll M, C. Nordman J, Levenson R. 2012. Dopamine Receptor Interacting Proteins: Targeting Neuronal Calcium Sensor-1/D2 Dopamine Receptor Interaction for Antipsychotic Drug Development. CDT. 13(1):72-79.
Kebabian JW, Tarazi FI, Kula NS, Baldessarini RJ. 1997. Compounds selective for dopamine receptor subtypes. Drug Discovery Today. 2(8):333-340.
Lachowicz JE, Sibley DR. 1997. Molecular Characteristics of Mammalian Dopamine Receptors. 81(3):105-113.
MISSALE C, NASH SR, ROBINSON SW, JABER M, CARON MG. 1998. Dopamine Receptors: From Structure to Function. Physiological Reviews. 78(1):189-225.
Neve KA, Neve RL. 1997. The Dopamine Receptors.
Neve KA, Seamans JK, Trantham-Davidson H. 2004. Dopamine Receptor Signaling. Journal of Receptors and Signal Transduction. 24(3):165-205.
Niznik HB, Sugamori KS, Clifford JJ, Waddington JL. 2002. D1-Like Dopamine Receptors: Molecular Biology and Pharmacology.121-158.
Tarazi FI, Zhang K, Baldessarini RJ. 2004. Dopamine D4Receptors: Beyond Schizophrenia. Journal of Receptors and Signal Transduction. 24(3):131-147.
Wang M, Wong AH, Liu F. 2012. Interactions between NMDA and dopamine receptors: A potential therapeutic target. Brain Research. 1476154-163.
Wu J, Xiao H, Sun H, Zou L, Zhu L. 2012. Role of Dopamine Receptors in ADHD: A Systematic Meta-analysis. Mol Neurobiol. 45(3):605-620.
Yang Z, Sibley DR, Jose PA. 2004. D5Dopamine Receptor Knockout Mice and Hypertension. Journal of Receptors and Signal Transduction. 24(3):149-164.